Exhibit 99.1
Joint Filing Agreement
The undersigned hereby agree that the Statement on Schedule 13G dated February 2, 2017 with respect to the shares of Common Stock of Cascadian Therapeutics, Inc., and any further amendments thereto executed by each and any of the undersigned shall be filed on behalf of each of the undersigned pursuant to and in accordance with the provisions of Rule 13d-1(k)(1) under the Securities Exchange Act of 1934, as amended.
Dated: February 2, 2017
| BIOTECHNOLOGY VALUE FUND, L.P. | ||||
| BVF INC. | ||||
| By: | BVF Partners L.P., its general partner | |||
| By: | BVF Inc., its general partner | By: | /s/ Mark N. Lampert | |
| Mark N. Lampert | ||||
| By: | /s/ Mark N. Lampert | President | ||
| Mark N. Lampert | ||||
| President | ||||
/s/ Mark N. Lampert | ||||
| MARK N. LAMPERT | ||||
| BIOTECHNOLOGY VALUE FUND II, L.P. | ||||
| By: | BVF Partners L.P., its general partner | |||
| By: | BVF Inc., its general partner | |||
| By: | /s/ Mark N. Lampert | |||
| Mark N. Lampert | ||||
| President | ||||
| BVF PARTNERS L.P. | ||||
| By: | BVF Inc., its general partner | |||
| By: | /s/ Mark N. Lampert | |||
| Mark N. Lampert | ||||
| President | ||||
| BVF PARTNERS OS LTD. | ||||
| By: | BVF Partners L.P., its sole member | |||
| By: | BVF Inc., its general partner | |||
| By: | /s/ Mark N. Lampert | |||
| Mark N. Lampert | ||||
| President | ||||
| BIOTECHNOLOGY VALUE TRADING FUND OS LP | ||||
| By: | BVF Partners L.P., its investment manager | |||
| By: | BVF Inc., its general partner | |||
| By: | /s/ Mark N. Lampert | |||
| Mark N. Lampert | ||||
| President | ||||